Planning the End of Ortho-K Treatment

By Dr. Mark PageAugust 3, 20265 min read

Every myopia control program ends eventually, and almost nobody plans for it. Families arrive focused on starting, and the question of stopping surfaces years later when a teenager leaves for university or a prescription appears to have settled. Whether stopping causes a burst of accelerated growth is one of the more genuinely contested questions in the field. This article sets out what rebound means, what the evidence does and does not establish, which patients are more likely to be affected, and how to design an exit that does not squander the benefit accumulated over years.

On this page

What Rebound Actually Means

Does myopia rebound after stopping Ortho-K?

Rebound means axial elongation accelerating beyond the expected age-adjusted rate after treatment stops, which would partially erode the benefit accumulated during treatment. The phenomenon is well described for higher-concentration atropine. For Ortho-K the evidence is mixed: some studies report a period of faster growth after cessation, others find growth resuming at a rate appropriate for the child's age. Age at discontinuation appears to matter more than treatment duration.

It is important to separate two things that get conflated. The corneal shape returns to baseline within one to two weeks of stopping, and vision returns to needing correction. That is not rebound, it is simply the treatment wearing off, and it is expected. Rebound refers specifically to the underlying growth of the eyeball, which is a slower and less visible process.

What the Evidence Shows and Does Not

The honest position is that this question is not settled, and here is the shape of the disagreement.

Atropine rebound is reasonably well established, particularly at higher concentrations, which is part of the rationale for low-dose protocols and for tapering rather than stopping abruptly.
Ortho-K studies of discontinuation are fewer and smaller. Some report a period of accelerated elongation in the months after stopping, especially in younger children. Others report growth resuming at an age-appropriate rate.
Study designs differ in ways that matter. Children who discontinue in a study are often those who stopped for a reason, which may itself relate to progression.
Even where rebound occurs, it appears partial. The literature does not support the idea that accumulated benefit is entirely lost, but it also cannot promise that none of it is.

This is a case where the correct answer to a parent question is that we do not fully know, followed by a plan that is robust to either outcome. The broader discussion of how to read this literature is in what the research shows.

Who Is at Higher Risk

The factors that raise concern about stopping are largely the same ones that made treatment worthwhile in the first place.

Factors that influence discontinuation risk
Factor	Lower concern	Higher concern
Age at stopping	Late teens or older	Under about fourteen
Recent progression rate	Flat across several visits	Still measurably elongating
Family history	No myopic parents	Two myopic parents
Current degree of myopia	Low	Moderate to high
Reason for stopping	Planned, after documented stability	Abrupt, due to cost or frustration

Factors that influence discontinuation risk

The bottom row is the one families control. Stopping because a program became unaffordable or because a teenager grew tired of the routine puts a child in the higher-concern column for reasons that have nothing to do with their eyes. Raising either issue early usually produces better options than quitting quietly.

Designing an Exit

A planned discontinuation looks quite different from simply stopping, and the difference is mostly in what gets measured.

1
Confirm stability first
Look for minimal axial change across at least two or three consecutive measurement intervals before considering discontinuation at all.
2
Choose the timing deliberately
Avoid stopping during a period of rapid growth or in the middle of a school year when monitoring will be harder to maintain.
3
Consider a wind-down rather than a stop
Some patients reduce to alternate nights for a period. This is not strongly evidence-based but it is low risk and preserves the option to resume.
4
Allow the washout and re-baseline
After several weeks out of lenses, take a fresh refraction and corneal map so the post-treatment starting point is documented.
5
Keep measuring for at least a year
Axial length at six and twelve months after stopping is what tells you whether rebound occurred. Without it, the decision was made blind.
6
Keep the door open
If measurements show acceleration, resuming treatment is straightforward and remains a genuine option.

When Stopping Is the Right Call

None of this argues for continuing indefinitely. There are good reasons to stop and they should not be treated as failures.

Documented stability over a sustained period in an older teenager or young adult is the textbook reason.
Recurrent ocular surface problems or repeated compliance difficulty may make continuing inappropriate on safety grounds.
A switch to another treatment, including refractive surgery once the eye has stabilised, is a transition rather than an abandonment.
Genuine unwillingness on the part of an older teenager. A treatment that is resented is a treatment that will be skipped, and that carries its own risk.

Many patients also continue Ortho-K into adulthood purely because they prefer waking up able to see, long after the myopia control rationale has expired. That is a perfectly reasonable use of the treatment and is covered in Ortho-K for adults.

Frequently Asked Questions

Will my child vision be worse than before they started?

Their prescription after several years will usually be higher than when they started, because myopia progressed during those years even while being slowed. That is not caused by Ortho-K.

The relevant comparison is against where they would have been without treatment, which is why baseline and serial axial length data matter so much.

Can we take a summer off from lens wear?

A short planned break is not the same as discontinuation and is sometimes reasonable, for example during a course of treatment for an unrelated eye condition.

Expect vision to return to baseline within a couple of weeks, and expect to resume with a check rather than simply restarting after a long gap.

Does tapering to alternate nights actually help?

The evidence for tapering in Ortho-K specifically is limited. It is a reasonable, low-risk approach borrowed from atropine practice rather than a proven protocol.

What it does reliably provide is a period during which measurements can be taken while treatment could still be resumed easily.

What do we do if rebound does happen?

Resume treatment. Ortho-K can be restarted, usually with a fresh evaluation and often with new lenses if the prescription has moved.

This is the practical argument for continuing measurement after stopping. Rebound that is measured can be responded to, and rebound that is not measured cannot.

Last updated August 23, 2026. Clinically reviewed by Dr. Mark Page.